Today: 29 April 2026
Uranium Boom or Bust? Denison Mines (DNN) Stock Soars on Nuclear Revival – Full 2025 Analysis
6 November 2025
3 mins read

Denison Mines (DNN) Q3 2025 Earnings Today: What to Watch as Wheeler River Faces Judicial Review

TORONTO — November 6, 2025 — Denison Mines Corp. (NYSE American: DNN; TSX: DML) is slated to report third‑quarter 2025 results today, capping a news‑packed week that includes a legal challenge tied to its flagship Wheeler River uranium project in Saskatchewan. Here’s everything investors need to know today—from the earnings setup and key catalysts to how the stock is trading.

At a glance

  • Earnings day: Denison’s investor calendar lists Q3 2025 reporting today (Nov. 6, 2025); several third‑party calendars also show an earnings call scheduled for this morning. 
  • Fresh legal overhang: On Nov. 4, Denison acknowledged a judicial review application filed by Peter Ballantyne Cree Nation that seeks to set aside Saskatchewan’s provincial environmental assessment (EA) approval for Wheeler River. Denison says it will vigorously defend against the claims. 
  • Stock action: On the Toronto Stock Exchange, DML shares crossed above the 200‑day moving average this week, a technical milestone noted by MarketBeat. (See live U.S. quote above.) 

Earnings: setup and expectations

  • When: Denison’s Financial Calendar pegs the Q3 2025 report to Thursday, Nov. 6, 2025
  • Where expectations sit: One data provider tracking S&P estimates shows one analyst modeling CAD ~1.10 million in revenue and EPS of ~‑CAD 0.024 for Q3. Treat these as directional, not definitive, until the company posts official results. 
  • Call timing: Several third‑party calendars list a morning call for today; note that outlets sometimes differ on before‑market versus after‑market labels, so always defer to Denison’s investor page for final details. 

What to listen for on the call

  1. Regulatory path at Wheeler River. The Canadian Nuclear Safety Commission (CNSC) scheduled a two‑part hearing for the Wheeler River EA & construction licence—Part 1 on Oct. 8 and Part 2 during the week of Dec. 8, 2025. Any color on timing or conditions for approvals will be closely parsed. 
  2. Impact of the judicial review. Management’s view on potential timelines, scope, and next steps related to the PBCN application will be key. Denison says it believes consultation to date has been thorough and intends to defend vigorously. 
  3. Liquidity and project funding. In August, Denison closed US$345M in convertible senior notes due 2031 with a 4.25% coupon; the notes carry an initial conversion price of US$2.92 per share and an effective capped‑call conversion level up to US$4.32—all of which buttresses the company’s balance sheet heading into construction decisions. Updates on cash, capex and spend cadence will matter. 
  4. Operations & milestones. Expect updates on the Phoenix ISR detailed engineering and on McClean Lake, where SABRE mining restarted in 2025 through the Orano‑Denison JV. 

The week’s other headline: judicial review filed

On Nov. 4, Denison said it was served with a judicial review application from Peter Ballantyne Cree Nation that challenges the province’s EA approval for Wheeler River and asks the court to remit the decision to the Saskatchewan environment minister for reconsideration. Denison highlighted its Indigenous engagement efforts and stated it denies the claims and will vigorously defend its position. The filing comes as federal licensing hearings proceed at the CNSC. 

Why it matters: Provincial EA approval (received in August) is a major step; the CNSC hearings in October and December are part of the final federal approval process covering the EA and licence to prepare and construct. A judicial review does not itself decide the merits of the project but can influence timing and process. 


Stock today: technical tailwinds, macro backdrop

Denison’s DML shares on the TSX moved above their 200‑day moving average this week—a level technicians watch for momentum confirmation. In parallel, uranium‑exposed equities continue to trade with sensitivity to policy and fuel‑cycle headlines. (For real‑time U.S. trading in DNN, see the live chart above.) 


Where the story goes next

  • Federal hearings wrap in December. Watch for outcomes and any conditions from the CNSC sessions (Part 2 the week of Dec. 8). 
  • Q3 print and guideposts. Today’s release should update cash, spending and Phoenix ISR readiness—and may address how legal proceedings intersect with the build schedule. 
  • Balance‑sheet firepower. The US$345M convert proceed details suggest Denison has flexibility as it approaches final build approvals and early‑works decisions. 

Background: what Denison does

Denison is a Canadian uranium developer focused on Saskatchewan’s Athabasca Basin. Its Wheeler River project—hosting the Phoenix (ISR) and Gryphon deposits—is often described as the largest undeveloped uranium project in the eastern Athabasca Basin. The company also owns 22.5% of the McClean Lake joint venture (with Orano), where SABRE mining restarted in 2025. 


Editor’s note and disclosures

  • Information in this article reflects publicly available sources as of Nov. 6, 2025. For final timing and dial‑in details, refer to Denison’s investor relations pages. 
  • This article is for information only and not investment advice.

Sources: Denison Mines investor calendar and press releases; CNSC scheduling pages; third‑party earnings calendars and market coverage; MarketBeat technical note on TSX: DML; Orano/Denison SABRE update. Key documents linked inline via citations. 

Stock Market Today

  • Humana Stock Dips Over 2% Amid Profit Forecast Revision
    April 29, 2026, 9:26 AM EDT. Humana Inc. (HUM) stock dropped more than 2% premarket after the health insurer maintained its adjusted full-year profit forecast at $9 per share but lowered its nonadjusted earnings estimate to at least $8.36 from $8.89. The company reported a 23% rise in first-quarter revenue and adjusted earnings per share beating expectations. However, charges from a multiyear transformation program to realign costs and operations weighed on results. Rising medical and pharmaceutical expenses, coupled with tighter government rules on Medicare Advantage payments, have pressured the sector. Humana, a major Medicare Advantage provider, faces ongoing margin challenges. Year to date, Humana shares have fallen about 13% amid these industry headwinds.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
PENN Entertainment Q3 2025: $1.72B Revenue, GAAP Loss of $6.03/Share as Company Ends ESPN Bet Alliance and Pivots to iCasino
Previous Story

PENN Entertainment Q3 2025: $1.72B Revenue, GAAP Loss of $6.03/Share as Company Ends ESPN Bet Alliance and Pivots to iCasino

Fitell (FTEL) Secures $50M Convertible Note to Launch ‘2F Robotics,’ Will Hold Proceeds in Stablecoins — Nov. 6, 2025
Next Story

Fitell (FTEL) Secures $50M Convertible Note to Launch ‘2F Robotics,’ Will Hold Proceeds in Stablecoins — Nov. 6, 2025

Go toTop